. Overview We are a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in order to create new development opportunities. We prioritize creativity, integrity and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment opti...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001213900-26-025433 | EDGAR | 83K words |
| 2025-03-05 | 2024-12-31 | 0001213900-25-020368 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001213900-24-021982 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001213900-23-018373 | EDGAR | — |
| 2022-03-09 | 2021-12-31 | 0001213900-22-011208 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001213900-21-014709 | EDGAR | — |
| 2020-03-20 | 2019-12-31 | 0001171843-20-001860 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001171843-19-001687 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001171843-18-001934 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001171843-17-001555 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001213900-25-107881 | EDGAR | 22K words |
| 2025-08-11 | 2025-06-30 | 0001213900-25-073942 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001213900-25-040811 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001213900-24-096252 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001213900-24-065380 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001213900-24-038757 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0001213900-23-083013 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001213900-23-062782 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001213900-23-036113 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001213900-22-069010 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001213900-22-045922 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001213900-22-024238 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001213900-26-035971 | EDGAR | 1K words |
| 2026-03-10 | 0001213900-26-025432 | EDGAR | — |
| 2026-02-24 | 0001213900-26-019617 | EDGAR | — |
| 2025-12-15 | 0001213900-25-121687 | EDGAR | — |
| 2025-12-08 | 0001213900-25-119242 | EDGAR | — |
| 2025-12-03 | 0001213900-25-117577 | EDGAR | — |
| 2025-11-19 | 0001213900-25-112383 | EDGAR | — |
| 2025-11-10 | 0001213900-25-107873 | EDGAR | — |
| 2025-08-11 | 0001213900-25-073937 | EDGAR | — |
| 2025-06-12 | 0001213900-25-053844 | EDGAR | — |
207 total filings indexed. 175 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001359931 |
| Ticker | TARA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.protaratx.com |
| Listed | 2020-01-10 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report